English

Interim Report 1 January – 30 September 2021

Report this content

Another strong quarter!

1 JULY – 30 SEPTEMBER 2021 (3 MONTHS)

  • Net sales increased by 49 percent to SEK 1,850m (1,241), of which acquired growth amounted to 54 percent. The organic sales decreased by 5 percent, but excluding net sales related to COVID-19, organic growth amounted to 9 percent.
  • EBITA increased by 44 percent to SEK 286m (199), corresponding to an EBITA-margin of 15.5 percent (16.1).
  • Profit after tax increased by 8 percent to SEK 139m (127).
  • Earnings per share amounted to SEK 1.13 (1.14).
  • Cash flow from operating activities amounted to SEK 233m (183).
  • One acquisition was completed during the quarter, Bio-Connect Group. The acquisition is expected to add annual net sales of SEK 140m.

1 JANUARY – 30 SEPTEMBER 2021 (9 MONTHS)

  • Net sales increased by 65 percent to SEK 5,862m (3,542), of which acquired growth amounted to 46 percent. The organic sales was 22 percent, but excluding net sales related to COVID-19, organic growth amounted to 6 percent.
  • EBITA increased by 94 percent to SEK 944m (486), corresponding to an EBITA-margin of 16.1 percent (13.7).
  • Profit after tax increased by 80 percent to SEK 543m (301).
  • Earnings per share amounted to SEK 4.58 (2.69). Earnings per share for the last 12 months amounted to SEK 6.50 (4.63).
  • Cash flow from operating activities amounted to SEK 617m (391).
  • The equity ratio was 40 percent (46).
  • Return on working capital (P/WC) amounted to 105 percent (103).
  • Three acquisitions were completed during the interim period, Vision Ophtalmology Group, Healthcare 21 Group and Bio-Connect Group. The acquisitions are expected to add annual net sales of SEK 2,540m.

Stockholm, 22 October 2021 AddLife AB (publ)


For more information, contact;
Kristina Willgård, CEO, kristina.willgard@add.life, +46 70 510 12 23
Martin Almgren, CFO, martin.almgren@add.life, +46 70 228 15 45
www.add.life


Teleconference
Investors, analysts and the media are invited to a teleconference at which CEO Kristina Willgård and CFO Martin Almgren will present the interim report. The presentation will be given in English and take about 20 minutes. after which there will be an opportunity to ask questions. The meeting will be recorded and made available online. If this is your first time using Teams, you will be asked to download an app.

The teleconference will be at 10 a.m. on 22 October 2021

If you wish to participate via teleconference, please follow this link>>
Or call in (only sound) +46 8 505 376 58 Conference-ID: 238 396 409#

The presentation is also available on AddLife YouTube >>


AddLife is an independent player in the Life Science industry that offers high-quality products, services and advice to both the private and public sectors, mainly in the Nordic region and rest of Europe. AddLife has about 1,800 employees in some 70 operating subsidiaries. The Group currently has net sales of around SEK 7 billion. AddLife shares are listed on Nasdaq Stockholm.

This information is information that AddLife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 22 October 2021 at 07:45 a.m. CET.

Subscribe

Documents & Links